Mega Lifesciences Public Company Limited Net Assets
Mega Lifesciences Public Company Limited net assets. Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA) has net assets worth ฿10.34 Billion THB (≈ $322.41 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (฿16.15 Billion ≈ $503.30 Million USD) and total liabilities (฿5.80 Billion ≈ $180.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Mega Lifesciences Public Company Limited (MEGA) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ฿10.34 Billion |
| % of Total Assets | 64.06% |
| Annual Growth Rate | 18.03% |
| 5-Year Change | 27.29% |
| 10-Year Change | 118.28% |
| Growth Volatility | 30.87 |
Net Assets of Mega Lifesciences Public Company Limited (2010–2025)
Net assets of Mega Lifesciences Public Company Limited from 2010 to 2025. This chart illustrates how Mega Lifesciences Public Company Limited's net assets have evolved over time, based on quarterly financial data. See MEGA equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Mega Lifesciences Public Company Limited (2010–2025)
The table below shows the annual net assets of Mega Lifesciences Public Company Limited from 2010 to 2025. For live market cap and overall valuation, see Mega Lifesciences Public Company Limited stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ฿10.22 Billion ≈ $318.40 Million |
+3.43% |
| 2024-12-31 | ฿9.88 Billion ≈ $307.85 Million |
+6.18% |
| 2023-12-31 | ฿9.30 Billion ≈ $289.94 Million |
+5.99% |
| 2022-12-31 | ฿8.78 Billion ≈ $273.56 Million |
+9.37% |
| 2021-12-31 | ฿8.03 Billion ≈ $250.14 Million |
+14.99% |
| 2020-12-31 | ฿6.98 Billion ≈ $217.53 Million |
+13.02% |
| 2019-12-31 | ฿6.18 Billion ≈ $192.47 Million |
+7.87% |
| 2018-12-31 | ฿5.72 Billion ≈ $178.42 Million |
+9.15% |
| 2017-12-31 | ฿5.24 Billion ≈ $163.46 Million |
+12.06% |
| 2016-12-31 | ฿4.68 Billion ≈ $145.87 Million |
+7.96% |
| 2015-12-31 | ฿4.33 Billion ≈ $135.11 Million |
+8.96% |
| 2014-12-31 | ฿3.98 Billion ≈ $124.00 Million |
+7.74% |
| 2013-12-31 | ฿3.69 Billion ≈ $115.09 Million |
+127.06% |
| 2012-12-31 | ฿1.63 Billion ≈ $50.69 Million |
+23.36% |
| 2011-12-31 | ฿1.32 Billion ≈ $41.09 Million |
+55.11% |
| 2010-12-31 | ฿849.90 Million ≈ $26.49 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mega Lifesciences Public Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 833.4% over the analyzed period, indicating profitable operations and earnings retention.
Mega Lifesciences Public Company Limited Net Assets Breakdown (December 2025)
Mega Lifesciences Public Company Limited net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ฿8.28 Billion | 81.04% |
| Common Stock | ฿435.94 Million | 4.27% |
| Other Comprehensive Income | ฿-804.02 Million | -7.87% |
| Other Components | ฿2.30 Billion | 22.56% |
| Total Equity | ฿10.22 Billion | 100.00% |
Mega Lifesciences Public Company Limited Competitors by Market Cap
The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sabine Royalty Trust
NYSE:SBR
|
$958.15 Million |
|
Rio Tinto PLC
LSE:RIO
|
$958.33 Million |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
$958.41 Million |
|
Jiangsu Dagang Co Ltd
SHE:002077
|
$958.78 Million |
|
Marten Transport Ltd
NASDAQ:MRTN
|
$957.86 Million |
|
Rastar Environmental Protection Materials Co.Ltd.
SHE:300834
|
$957.25 Million |
|
Seegene Inc
KQ:096530
|
$957.23 Million |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
$957.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mega Lifesciences Public Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,876,759,000 to 10,215,187,000, a change of 338,428,000 (3.4%).
- Net income of 1,911,984,000 contributed positively to equity growth.
- Dividend payments of 1,394,980,000 reduced retained earnings.
- Other comprehensive income decreased equity by 892,226,999.
- Other factors increased equity by 713,650,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ฿1.91 Billion | +18.72% |
| Dividends Paid | ฿1.39 Billion | -13.66% |
| Other Comprehensive Income | ฿-892.23 Million | -8.73% |
| Other Changes | ฿713.65 Million | +6.99% |
| Total Change | ฿- | 3.43% |
Book Value vs Market Value Analysis
This analysis compares Mega Lifesciences Public Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.86x to 3.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | ฿1.77 | ฿35.25 | x |
| 2012-12-31 | ฿2.20 | ฿35.25 | x |
| 2013-12-31 | ฿4.94 | ฿35.25 | x |
| 2014-12-31 | ฿4.60 | ฿35.25 | x |
| 2015-12-31 | ฿5.01 | ฿35.25 | x |
| 2016-12-31 | ฿5.39 | ฿35.25 | x |
| 2017-12-31 | ฿6.04 | ฿35.25 | x |
| 2018-12-31 | ฿6.59 | ฿35.25 | x |
| 2019-12-31 | ฿7.09 | ฿35.25 | x |
| 2020-12-31 | ฿7.98 | ฿35.25 | x |
| 2021-12-31 | ฿9.18 | ฿35.25 | x |
| 2022-12-31 | ฿10.07 | ฿35.25 | x |
| 2023-12-31 | ฿10.67 | ฿35.25 | x |
| 2024-12-31 | ฿11.36 | ฿35.25 | x |
| 2025-12-31 | ฿11.72 | ฿35.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mega Lifesciences Public Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.72%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.51%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 1.57x
- Recent ROE (18.72%) is below the historical average (21.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 35.19% | 9.39% | 1.48x | 2.54x | ฿326.33 Million |
| 2012 | 34.66% | 9.31% | 1.44x | 2.58x | ฿395.32 Million |
| 2013 | 16.90% | 8.87% | 1.08x | 1.77x | ฿254.76 Million |
| 2014 | 13.77% | 7.09% | 1.15x | 1.69x | ฿150.05 Million |
| 2015 | 16.05% | 8.76% | 1.04x | 1.76x | ฿262.28 Million |
| 2016 | 16.99% | 9.02% | 1.11x | 1.70x | ฿326.93 Million |
| 2017 | 21.22% | 11.59% | 1.10x | 1.66x | ฿588.36 Million |
| 2018 | 21.07% | 11.66% | 1.07x | 1.68x | ฿633.58 Million |
| 2019 | 18.44% | 10.23% | 1.06x | 1.71x | ฿521.02 Million |
| 2020 | 20.02% | 11.06% | 1.09x | 1.67x | ฿696.89 Million |
| 2021 | 24.33% | 13.77% | 1.07x | 1.66x | ฿1.15 Billion |
| 2022 | 25.54% | 14.29% | 1.07x | 1.67x | ฿1.36 Billion |
| 2023 | 21.42% | 12.71% | 1.08x | 1.56x | ฿1.06 Billion |
| 2024 | 20.38% | 13.12% | 1.08x | 1.44x | ฿1.02 Billion |
| 2025 | 18.72% | 13.51% | 0.88x | 1.57x | ฿890.47 Million |
Industry Comparison
This section compares Mega Lifesciences Public Company Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,303,518,956
- Average return on equity (ROE) among peers: 5.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mega Lifesciences Public Company Limited (MEGA) | ฿10.34 Billion | 35.19% | 0.56x | $957.93 Million |
| Eternal Energy Public Company Limited (EE) | $1.30 Billion | -11.22% | 0.00x | $36.39 Million |
| Mega Lifesciences Public Company Limited (MEGA-R) | $9.30 Billion | 21.42% | 0.56x | $869.61 Million |
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It offers wellness and nutrition products, includi… Read more